1. Home
  2. ALT vs TCI Comparison

ALT vs TCI Comparison

Compare ALT & TCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALT
  • TCI
  • Stock Information
  • Founded
  • ALT 1997
  • TCI 1983
  • Country
  • ALT United States
  • TCI United States
  • Employees
  • ALT N/A
  • TCI N/A
  • Industry
  • ALT Biotechnology: Pharmaceutical Preparations
  • TCI Real Estate
  • Sector
  • ALT Health Care
  • TCI Finance
  • Exchange
  • ALT Nasdaq
  • TCI Nasdaq
  • Market Cap
  • ALT 292.0M
  • TCI 357.8M
  • IPO Year
  • ALT N/A
  • TCI N/A
  • Fundamental
  • Price
  • ALT $3.83
  • TCI $45.60
  • Analyst Decision
  • ALT Strong Buy
  • TCI
  • Analyst Count
  • ALT 6
  • TCI 0
  • Target Price
  • ALT $17.40
  • TCI N/A
  • AVG Volume (30 Days)
  • ALT 3.0M
  • TCI 1.8K
  • Earning Date
  • ALT 08-12-2025
  • TCI 08-07-2025
  • Dividend Yield
  • ALT N/A
  • TCI N/A
  • EPS Growth
  • ALT N/A
  • TCI 11.20
  • EPS
  • ALT N/A
  • TCI 0.76
  • Revenue
  • ALT $20,000.00
  • TCI $47,730,000.00
  • Revenue This Year
  • ALT N/A
  • TCI N/A
  • Revenue Next Year
  • ALT $761,880.20
  • TCI N/A
  • P/E Ratio
  • ALT N/A
  • TCI $61.66
  • Revenue Growth
  • ALT N/A
  • TCI N/A
  • 52 Week Low
  • ALT $2.90
  • TCI $25.50
  • 52 Week High
  • ALT $11.16
  • TCI $48.00
  • Technical
  • Relative Strength Index (RSI)
  • ALT 51.79
  • TCI 56.33
  • Support Level
  • ALT $3.35
  • TCI $46.00
  • Resistance Level
  • ALT $3.66
  • TCI $48.00
  • Average True Range (ATR)
  • ALT 0.19
  • TCI 0.80
  • MACD
  • ALT 0.07
  • TCI 0.05
  • Stochastic Oscillator
  • ALT 86.18
  • TCI 67.90

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

About TCI Transcontinental Realty Investors Inc.

Transcontinental Realty Investors Inc is a fully integrated externally managed real estate company. It operates multifamily and commercial properties throughout the southern United States and also invests in mortgage notes receivable and in the land that is either held for appreciation or development. The company has two business segments: the acquisition, development, ownership, and management of multifamily properties which include the rental of apartments (Residential Segment) and other tenant services, including parking and storage space rental, and the acquisition, development, ownership, and management of commercial properties which are office properties(Commercial Segment). It includes the rental of office space and other tenant services, including parking and storage space rental.

Share on Social Networks: